Clinical trialNCT01928771CompletedPhase 3Interventional

Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

SponsorAstraZenecaEnrollment2,681Asthma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Eugene R. Bleecker, MD, Professor of Medicine
Center for Genomics and Personalized Medicine Research, Medical Center Boulevard, Winston-Salem, North Carolina 27157
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

275 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Research Site
Bedford Park, Australia
Research Site
Box Hill, Australia
Research Site
Clayton, Australia
Research Site
Concord, Australia
Research Site
Frankston, Australia
Research Site
Nedlands, Australia
Research Site
New Lambton Heights, Australia
Research Site
Parkville, Australia
Research Site
Prahran, Australia
Research Site
Randwick, Australia
Research Site
Woolloongabba, Australia

Brazil

Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Santo André, Brazil
Research Site
Sorocaba, Brazil
Research Site
São Paulo, Brazil

Bulgaria

Research Site
Dupnitsa, Bulgaria
Research Site
Pernik, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Rousse, Bulgaria
Research Site
Samokov, Bulgaria
Research Site
Sliven, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Stara Zagora, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Velingrad, Bulgaria
Research Site
Yambol, Bulgaria

Czechia

Research Site
Brno, Czechia
Research Site
Jindřichův Hradec, Czechia
Research Site
Karlovy Vary, Czechia
Research Site
Ostrava, Czechia
Research Site
Pardubice, Czechia
Research Site
Pilsen, Czechia
Research Site
Prague, Czechia
Research Site
Rokycany, Czechia
Research Site
Strakonice, Czechia
Research Site
Teplice, Czechia

France

Research Site
Brest, France
Research Site
Clermont-Ferrand, France
Research Site
Dijon, France

235 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Benralizumab →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Sept 2013
Primary completion: 5 Apr 2016
Completion: 5 Apr 2016
Last update posted: 3 May 2017
Registered enrollment: 2,681
Registry id: NCT01928771

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.